Lisbon, Hovione, the specialist integrated CDMO and the leader in spray drying and particle engineering, just completed significant expansions in Europe and the USA. The investments at its East Windsor, New Jersey, and Ringaskiddy, Cork, facilities will significantly increase Hovione’s global spray drying capacity and enhance the sites‘capabilities.
Ths latest round of investment reinforces Hovione’s position as the global leader in spray drying for pharma applications, an essential technology for enhancing drug solubility and bioavailability. Spray drying converts liquid solutions into fine powders, enabling improved dissolution and absorption of poorly water-soluble drugs. This process is particularly valuable for inhalable therapies and oral formulations with low bioavailability, helping to deliver more effective treatments and ensuring reliable, high-quality healthcare solutions for patients.
In New Jersey, the investment represents the first step of a multi-year site expansion program, aimed at advancing both spray drying and tableting capabilities. Simultaneously, the Cork facility saw its spray drying capacity increase nearly twofold. Combined, these efforts are creating over 40 new skilled jobs, driving growth and innovation across both locations.
Dr Jean-Luc Herbeaux, Chief Executive Officer of Hovione said: “These expansions, incorporating our latest technologies, reflect Hovione’s unwavering commitment to innovation and manufacturing service excellence. Strengthening our facilities and teams in the USA and Ireland allows us to better serve our customers and provide flexible supply options for both small- and large-scale programs. By increasing our capacity and enhancing our technological capabilities, we are even better equipped to help our customers bring new and more complex drugs to market.”
The investments at both sites are part of Hovione’s long-term strategy to remain at the forefront of pharmaceutical technology. With a 65-year history of continuous improvement, Hovione is driving progress in drug development and manufacturing, offering solutions that enable more effective treatments and improved patient outcomes.
